The Competition Commission of India said in a Tweet that it has approved the formation of Johnson & Johnson's joint venture with Google in surgical robotics.
Novartis is looking to distinguish its new med Cosentyx from a bevy of next-gen psoriasis-fighters with additional nods, including one for ankylosing spondylitis. But it's not the only company with that idea.
Novartis is aiming to distinguish new psoriasis med Cosentyx from the rest of the next-gen field by building up its label, adding nods for conditions including ankylosing spondylitis. But it'll have some competition in that space, too.
Johnson & Johnson has heard the advice before: Split up and reap the benefits. This time, it's CNBC 's Jim Cramer making the call, and he figures the sum of J&J's parts would be 50% bigger than the whole is now. And he thinks an activist investor might step in and give J&J a push in that direction.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
For the second quarter of the year, Johnson & Johnson as usual has the pole position on reporting, and CEO Alex Gorsky was on hand with a midyear update.
Although the waning Ebola outbreak had Big Pharmas struggling to find volunteers for their Ebola vaccine trials, two new Phase II trials are going forward. GlaxoSmithKline will take its candidate to Senegal, while Johnson & Johnson and partner Bavarian Nordic will test their vaccine in France and the U.K.
Two Johnson & Johnson consumer health plants that operate under a consent decree from the FDA will no longer need to be monitored by outsiders, and the plant that was ground zero for the company's consumer health quagmire is expected to go back online after being sidelined for 5 years to regain standing with the FDA.
Johnson & Johnson is moving closer to resolving its consumer healthcare woes, preparing to reopen a Philadelphia-area factory that was once at the center of the drama.
Johnson & Johnson knows that "competition in the immunology space is fierce," as CEO Alex Gorsky admitted on the company's second-quarter conference call. After all, companies developing next-gen psoriasis-fighters have recently been going head-to-head against the company's Stelara to prove their efficacy. But the New Jersey pharma giant isn't planning on being left behind.